| abstract |
The present invention provides an activatable anti-human CTLA-4 antibody comprising a heavy chain comprising a VH domain and a light chain comprising a masking portion (MM), a cleavable portion (CM) and a VL domain. Such activatable anti-human CTLA-4 antibodies have CTLA-4 binding activity in the tumor microenvironment, wherein the masking moiety is removed by proteolytic cleavage of the cleavable moiety by a tumor-specific protease. ), Shows significantly reduced binding to CTLA-4 outside of the tumor. In this way, the activatable anti-human CTLA-4 antibody of the present invention reduces side effects associated with extra-tumor anti-CTLA-4 activity while retaining anti-tumor activity. |